论文部分内容阅读
免疫抑制剂种类繁多,但人们更为重视的是脏器同种移植免疫反应的抑制剂。本文主要就这类免疫抑制剂的概况,以及最近问世的免疫抑制剂环孢多肽A(Cyclosporin A)和优青糖苷(Bladinin)做一介绍。临床脏器移植的现状目前全世界临床进行的心、肝移植病例约有500例,胰移植约有200例,肾移植约有40,000例。日本几乎仅限于肾移植,但各种脏器同种(指人到人)移植水平每年都有提高。要使同种脏器移植成功,手术技术虽是关健,但更主要的还是要能完全抑制移植免疫反应,而又不产生副作用。免疫反应是机
A wide range of immunosuppressive agents, but people pay more attention to the organ allograft immune response inhibitors. This article focuses on the general situation of these immunosuppressants and the recently introduced immunosuppressive agents Cyclosporin A and Bladinin. Current Situation of Clinical Organ Transplantation At present, there are about 500 cases of heart and liver transplantation in the world, about 200 cases of pancreas transplantation and about 40,000 cases of kidney transplantation. Japan is almost exclusively limited to kidney transplants, but all kinds of organs (referring to human beings) have been upgraded every year. To make the same kind of organ transplant success, although the surgical technique is crucial, but more important is to be able to completely suppress the immune response, without causing side effects. Immune response is machine